---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-136748"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2022-05-02T23:59:59+00:00"
generated_at: "2026-06-26T02:07:45.439018+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Magenta Therapeutics enters amended employment agreements with two executives

## Summary
- Thomas Beetham (CLO) base salary $435,000, target incentive 40% of base, amended severance details.
- David Nichols (CTO) base salary $362,000, target incentive 40% of base, amended severance details.
- Severance: 0.75x base plus pro-rata target outside change in control; 1x base plus 100% target and accelerated vesting within change in control period.
- Agreements effective May 2, 2022, supersede prior employment agreements.
- Standard COBRA subsidies included; subject to release and noncompetition covenant.

## SEC filing metadata
- accession: 0001193125-22-136748
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2022-05-02T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312522136748/0001193125-22-136748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312522136748/d337873d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-136748
- JSON: https://secwatch.observer/filing/0001193125-22-136748.json
- Plain text: https://secwatch.observer/filing/0001193125-22-136748.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.